Pharmaceutical Granules, also referred to as Pharmaceutical Formulation Intermediates (PFIs), are multiparticulate systems in which APIs are combined with excipients to create ready-to-use formulation intermediates for oral solid dosage (OSD) form manufacturing.

Granules (PFIs) are designed to improve processing efficiency and dosage accuracy in various oral solid dosage forms such as tablets and capsules.

Granumet SR is a sustained-release Pharmaceutical Formulation Intermediate (PFI) containing Metformin as the active pharmaceutical ingredient (API).

Granumet SR granules are specifically developed to enable sustained release of Metformin, addressing the high-dose requirement and gastrointestinal (GI) tolerability challenges commonly associated with conventional Metformin formulations.

Metformin API powder is difficult to process due to poor flowability, high dose bulk, and rapid drug release, which can increase the risk of gastrointestinal side effects and variability and inconsistency in formulation.

Metformin sustained-release granules (Granumet SR) offers improved handling and content uniformity while enabling sustained release of Metformin through excipients, making it more suitable for consistent, scalable manufacturing of controlled and sustained-release oral solid dosage forms (OSDs).

Granumet SR (Metformin Granules) is primarily used in the development of sustained-release tablets for the management of diabetes mellitus.

The multiparticulate nature of Metformin granules provides formulation flexibility, allowing customization of dose strength and sustained-release profiles to meet therapeutic requirements.

This reduces dosing frequency, minimizes peak-related side effects, and enhances patient adherence, which is critical for long-term diabetes management.

Gangwal Healthcare ensures the quality of Granumet SR (Metformin Granules) through controlled and sustained-release granulation processes and stringent quality checks to maintain consistent drug content and drug release performance.

Granumet SR is available in multiple grades with defined Metformin HCl strengths, such as 500 mg sustained-release granules designed for 645 mg, 670 mg, and 700 mg tablet weights, enabling formulators to select the appropriate grade based on dosage strength and formulation requirements while meeting regulatory standards.